Report Phase 2 proof-of-concept data for VX-147 in APOL1-mediated FSGS

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 29 Oct 2020
Due: 31 Dec 2021

Deadline
Met
Late
Not met
Today

What the company said

“Data from this study is expected in 2021.”

SourceVertex Pharmaceuticals Form 8-K press release, 2020-10-29
FilingSEC filing index
Deadline as statedin 2021
Deadline used31 Dec 2021, the last day of the stated period
TypeProject
Permanent referenceKI-C-2020-VRTX-006487
Cite as https://keptindex.org/c/KI-C-2020-VRTX-006487/ — this address never changes.

What we found

Evidence strength A What the grades mean

Filings state Vertex announced positive Phase 2 proof-of-concept data for VX-147 in APOL1-mediated FSGS in December 2021, before the 2021 deadline.

A
Vertex Pharmaceuticals 8-K filed 2022-01-26 Regulatory filing · published 26 Jan 2022 · retrieved 10 Oct 2026 · kept permanently by the SEC
“In December, Vertex announced that, in a Phase 2 proof-of-concept (POC) study in patients with APOL1-mediated focal segmental glomerulosclerosis (FSGS), VX-147 achieved” ✓ confirmed on the page
A
Vertex Pharmaceuticals 10-K filed 2022-02-09 Regulatory filing · published 9 Feb 2022 · retrieved 10 Oct 2026 · kept permanently by the SEC
“In December 2021, we announced that patients with APOL1-mediated FSGS treated with VX-147 on top of standard of care achieved a statistically significant, substantial, and clinically meaningful reduction of proteinuria in a Phase 2 proof-of-concept clinical trial.” ✓ confirmed on the page

Market reaction: the shares moved +5.3% against the S&P 500 over the three sessions around the disclosure (25 Jan 2022 to 28 Jan 2022). What this measures

Checked 10 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

1 versions

Version 1 · original · stated 29 Oct 2020

Deadline 31 Dec 2021 (“in 2021”) · wording expected
Version 2 · stated 2 Nov 2021

Deadline 31 Dec 2021 (“in the fourth quarter of 2021”) · wording firm

“Results from this study will be reported in the fourth quarter of 2021.”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: VX-147 Phase 2 proof-of-concept data in APOL1-mediated FSGS
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Vertex Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.